Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. 

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France

     GENTAUR France SARL
    9, rue Lagrange, 75005 Paris 
    Tel 01 43 25 01 50 
    Fax 01 43 25 01 60
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Germany

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA

    usa-flagGenprice Inc, Logistics
    547, Yurok Circle
    San Jose, CA 95123
    Phone/Fax: 

    (408) 780-0908 

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    skype chat

    GENPRICE Inc. invoicing/ accounting:
    6017 Snell Ave, Suite 357
    San Jose, CA. 96123

     

    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     

    Monday, 17 June 2013 11:11

    Vaccine against smoking?!

    Smoking624Nicotine degradation before reaching the heart and brain, innovative vaccine greatly reduces dependence on nicotine products, taking away the pleasant effects of their use.

    Smoking is a difficult habit to quit. It has been shown that the pharmacological and behavioral aspects of this, there is still a form of legal drugs, are similar to those of addiction to cocaine and heroin. But if you did not initially develop an addiction?

    Researchers from the Medical College of Cornell University, New York, have developed a drug that inhibits the effects of nicotine intoxication. Although it is only 0.6 to 3% by dry weight of most tobacco, nicotine is a very potent drug. Once entered in the blood, it needs 10 to 20 seconds to pass the blood-brain barrier. Despite this his speed, nicotine is powerless before the new detergent. The vaccine stimulates the liver to produce significant quantities of antibodies that destroy the nicotine molecule almost as soon as it enters the bloodstream. So totally disappears relaxing and calming effect of a cigarette.

    Similar mechanism therapies have long existed, but have a huge disadvantage - including regular, weekly administration of a cocktail of drugs that have very adverse effects and should be combined with immunosuppressants. The new product is applied only once and ensure sustainable long-term effects. The tool can be used both for prevention in young people at risk who would succumb to the habit, and in heavy smokers, have exhausted all other alternatives to combat addiction.

    Published in News

    Braasch Biotech announced that they have received the first patent for anti-somatostatin vaccine for the treatment of obesity in dogs and cats. This is the first patent granted for the treatment of obesity by the vaccine.

    gentaur-dog-vaccine-immunouHappily curious prevalence of obesity among farmers move in parallel with their pets. In the U.S., 52.5% of dogs and 58.3% of the cats are overweight. U.S. veterinarians warn that 80 million dogs at risk of arthritis, diabetes, hypertension and a number of cancers.

    Just like in humans, obesity in pets reached epidemic dimensions. Once reached the pathological condition, the animal needs the intervention of the holder in order to revert to a healthy weight. The vaccine is one of the few alternatives other than additional walks in the park. Yet its registration in the European Union, Brazil, Mexico, Canada, the USA and Japan.

    Braasch Biotech have an extensive portfolio of anti-somatostatin products for the treatment of a number of metabolic diseases.

    Published in News
    Friday, 31 May 2013 16:40

    Bird flu becomes resistant

    According to a study published in the journal The Lancet, confirmed the first cases of resistance in avian influenza virus strain N7N9 to Tamiflu and related drugs. The study, conducted by the team of Dr. Yang from the Shanghai Center for Public Health, has been described as one of the finest virology research done so far.

    flu-burung-largeThe team examined 14 people infected with the strain N7N9, and track viral load (the content of virus in the blood) in the course of treatment. All study participants developed pneumonia. Seven of them require assisted ventilation, and three others - from extracorporeal membrane oxygenation of the blood - a procedure in which blood is oxygenated using an external device, as the lungs do not function properly. Two of these patients die after the infection.

    Researchers found that 11 patients Tamiflu lowers viral load, while most seriously ill he continued to grow, even during treatment. According to the team, this means that the strain acquired resistance to Tamiflu, and maybe even the entire class of drugs called neuraminidase inhibitors.

    Assumption was later confirmed by genetic studies of viruses that detect mutations characteristic of neuraminidase inhibitor-resistant strains. This is the first study linking these mutations with resistance in strains N7N9. According to the authors, in all cases, early treatment provides the best chance of recovery.
     
    Earlier this month, reports surfaced that N7N9 strain can spread from person to person. According to the World Health Organization is currently developing a vaccine that provides immunity against the agent.

    Published in News

    coc-gentaur-molecular-products-researchIt is possible soon to be established treatment for cocaine dependence. Researchers at Cornell University, have developed a vaccine which prevents cocaine enters the brain and cause euphoria, thus helps the treatment of addiction. The vaccine provides effective treatment, even if the intake of cocaine to be repeated occasionally.

    Cornell researchers have successfully implemented vaccine in animal models and are very close to clinical trials in humans. According to Dr. Ronald Crystal, research should begin by the end of the year.

    Cocaine blocks the reverse capture of dopamine in the synaptic cleft, which connect the nerve cells to each other. Dopamine is a neurotransmitter that creates a feeling of pleasure and enjoyment. Increasing levels of dopamine in the synaptic cleft is responsible for the euphoria that occurs after taking cocaine.

    It prevents the excessive accumulation of domapin in synapses. It contains inactivated viruses on which is "attached" substance chemically resembling cocaine. This allows the immune system to recognize cocaine and his relatives compounds that neutralize it.

    For the occurrence of cocaine euphoria necessary cocaine molecules to occupy at least 47% of the dopamine in nerve cells. Of the vaccine in human primates show that cocaine molecules able to occupy less than 20% of dopamine transporters.

    Researchers expect the vaccine to be effective in humans, but still can not say how often you should be administered to maintain its effect. For now, just be sure that it will be necessary to apply booster doses.
     
    According to official data, in the U.S. there are 1.9 million people using cocaine, 1.4 million of whom are dependent on it. Every year there are over 2 million visits to emergency departments due to drug abuse. Almost 500,000 of them are making the cocaine. Anti-cocaine vaccine has the potential to drastically reduce this number.

    Published in News

    vaccine-gentaur-bullet-blender-gold-kronos-dio-targattThe dream of many scientists to create a vaccine against AIDS has failed. National Institutes of Health in the U.S. announced that it attempts to immunize volunteers with an experimental vaccine known as HVTN 505 is officially terminated, since it is clear that it does not prevent infection.

    Clinical trial began in 2009 and since then, 1,250 voluntary participants received vaccine and 1244 others - control infusion of placebo, both groups over a period of 24 weeks. Among all the volunteers in total, so far has 41 infected with HIV than those who received the vaccine and 30 infected than those who received placebo. The study focused mainly people who have unprotected sex.

    Vaccine strategy using "double whammy" that aimed to strengthen the immune system. Three initial injections are placed initially, and after 16 weeks - another injection containing genetic material which creates a molecule of the type produced by HIV in order to induce a response in the immune system against viruses. Scientists say the vaccine itself did not cause infection. After presenting the matter collected data and results collected until mid-April at the National Institute of Allergy and Infectious Diseases, which sponsored the clinical trial recommended stopping the attempt to create the vaccine. Volunteers will be monitored for 5 years, and the data will be analyzed for further information.

    Published in News

    Millions of lives have been changed over the past fourthy years because of advances in medical technology. From stem-cell research to reengineering the way we take our daily medications, all these developments have brought health care into the 21st century. There has been a vast disconnect between these improvements and the manufacturing processes used to provide influenza vaccines to the public.

    Shockingly, the method used to produce the influenza vaccine has not been significantly transformed since 1931, when vaccines used for preventive care were first introduced to the public.

    Influenza causes between 3,000 and 48,000 deaths and 190,000 hospitalizations in any given season, so it is critical to utilize the most effective production methods to create influenza vaccines to protect our communities. Until recently, all influenza vaccines available in the U.S. were produced by growing and harvesting the virus in chicken eggs. During the time this method has been successful, millions of eggs are needed to produce enough vaccine for our communities each year, requiring production to begin many months in advance. Once the virus strains are selected for the upcoming influenza season by the WHO (World Health Organization), and companies begin manufacturing the vaccine, it can take anywhere between 6 and 9 months to make the vaccine available to physicians or pharmacists.

    The egg-based manufacturing process has been working for us to date; however, there is a new process that raises the bar in influenza vaccine manufacturing, is less time-consuming and brings the manufacturing process into the digital age.

    Cell-culture technology is the latest production technique for influenza vaccine manufacturing, which involves growing the virus in cells from mammals, rather than chicken eggs. This method offers advantages over the conventional egg-based process:

    • Since no eggs need to be collected, vaccines can be produced and available to the public quicker, which is critical in case of a flu pandemic.

    • The process does not use any preservatives or antibiotics during production.

    Cell-culture technology has been successfully used to manufacture many other vaccines, including those distributed during the H1N1 pandemic, as well as vaccines for polio, rubella and hepatitis A. This technology also has been tried and tested in other countries, which have already approved and use cell-based influenza vaccines abroad. Recently, the FDA gave its stamp of approval to use the technology in influenza vaccines available in the U.S., with an approval of a cell-based seasonal influenza vaccine.

    It is important that such a fundamental vaccine that every American ages 6 months and older is advised to receive each year is available using the most cutting-edge technology. I am excited to see how this major advancement will help start a new chapter in the evolution of influenza prevention.

    Published in News